Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0268


Breakthrough blood test for early diagnosis, screening, patient monitoring and therapeutic response prediction.

Prof. Dr. Med Ernst Hanisch, MD.

Affiliation:Prof. Ernst Hanisch, Chefarzt und Ärztlicher Direktor, Klinik für Allgemein- Viszeral- und Endokrine Chirurgie, Asklepios Klinik Langen, Akademisches Lehrkrankenhaus der JWG-Universität Frankfurt, Röntgenstr 20, 63225 Langen .

Tel: 06103/912 61200; FAX: 06103/9121814,


The recent rapid development of next-generation sequencing (NGS) of circulating cell-free DNA method has revolutionized cancer research. This breakthrough non-invasive technological system raises potential major clinical implications, including early cancer diagnosis, screening, decision-making for overcoming primary and acquired therapeutic resistance as well as patient monitoring. Challenges and clinical potential are discussed in this article.

(Citation: Gastric & Breast Cancer 2018; 13(1): 43-48)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 March 2018